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The limitations of current basal insulin preparations include concerns related to their
pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and per-
ception of management complexity, including rigid dosing schedules. Insulin degludec
(IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic
properties compared to insulin glargine (IGlar) including a long half-life of 25 h and a
duration of action >42 h at steady state, providing a flat and stable blood glucose-lowering
effect when injected once daily. Evidence from phase 3a clinical trials with a treat-to-target
design in patients with type 1 and type 2 diabetes has shown that IDeg has similar efficacy to
IGlar, with a 9% and 26% reduction in risk of overall and nocturnal hypoglycaemia,
respectively (in the pooled population) during the entire treatment period, and a 16%
and 32% reduction during the maintenance period, respectively. Given its pharmacody-
namic properties, IDeg offers a broad dosing window, allowing for flexible dose adminis-
tration, if required. Two different formulations of IDeg are available (100 units/mL [U100]
and 200 units/mL), the latter providing the same IDeg dose as the U100 formulation in half
the injection volume. The unique pharmacokinetic profile of IDeg facilitates glycaemic
control while minimising the risk of nocturnal hypoglycaemia.
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The beneficial effect of improved glycaemic control, especially
early in a patient’s disease journey, has been demonstrated
to reduce the risk of long-term complications in patients with
type 1 (T1DM) and type 2 (T2DM) diabetes mellitus [1,2].
Whilst current recommendations call for individualised
glycaemic targets for patients with T1DM and T2DM [3,4],
evidence indicates there is inertia in escalation of therapy at
all stages of the disease process despite prolonged periods
of poor glycaemic control [5,6]. Although insulin therapy has
robust glucose-lowering efficacy, insulin treatment is often
underutilised in T2DM, or the dose titration remains inade-
quate [7]. This is primarily due to the fear of hypoglycaemia,
coupled with the restrictions on patients’ lifestyle that can
result from complex or inflexible dosing regimens [8,9]. New
basal insulin products with an improved pharmacodynamic
profile, including prolonged and consistent biological action,
lower risk of hypoglycaemia and more flexible dosing sche-
dules, are being developed to address these issues with the
ultimate objective of improving long-term glycaemic control
and the patient’s experience with basal insulin therapy.
Typically, basal insulin is used to maintain stable blood
glucose levels in the fasting or post-absorptive state, with
mealtime supplementation using a rapid-acting insulin
administered to control the postprandial rise in glucose levels.
The basal insulins, insulin glargine (IGlar) and insulin detemir
(IDet) both have advantages over neutral protamine Hagedorn
(NPH) insulin due to their longer half-lives, comparativelyreduced within-subject variability and fewer hypoglycaemic
episodes [10–12]. IGlar is recommended for once-daily dosing
and IDet for once- or twice-daily dosing; however, in clinical
practice, more frequent than once-daily dosing of either of
these basal insulin preparations may offer improved glycae-
mic control of blood glucose in some cases [13–17].
However, IDet and IGlar exhibit significant residual within-
patient variability in their pharmacokinetic and pharmacody-
namic profiles that can lead to less predictable glucose-
lowering effects, which in turn contributes to the increased
risk of hypoglycaemia and can undermine dose titration
[11,18,19]. Improvements in the pharmacokinetic properties
of basal insulin analogues would entail a prolonged duration
of action combined with a less variable pharmacodynamic
effect, which might lead to more predictable glycaemic
control, less hypoglycaemia and greater dosing flexibility.
2. Insulin degludec: Structure, mechanism of
action and pharmacokinetic properties
Insulin degludec (IDeg) is a new-generation basal insulin
analogue that is available in formulations of 100 units/mL
(U100) and 200 units/mL (U200), where the latter delivers the
same amount of insulin as U100 in half the injection volume.
Similar to IDeg U100, IDeg U200 is approved as a once-daily
dose regimen, thereby offering an additional and effective
option for patients with higher daily insulin requirements.
IDeg is derived by removal of the B30 threonine amino acid
residue, and acylating the now DesB30 human insulin at the
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glutamic acid spacer [20,21]. IDeg is formulated in the presence
of phenol and zinc to create a solution of di-hexamers.
Following subcutaneous (SC) injection and the dispersion of
phenol, the di-hexamers self-associate to form a stable depot
of multi-hexamer chains at the injection site (Fig. 1). The
subsequent diffusion of zinc from the multi-hexamers results
in gradual dissociation of these chains into readily-absorbed
IDeg monomers, providing a slow and continuous delivery of
IDeg into the circulation [20]. In addition, IDeg can bind
strongly but reversibly to albumin via its fatty di-acid side
chain, resulting in plasma protein binding of more than 99%
[22]. As the concentration of IDeg is very low compared to
albumin (>10,000-fold), IDeg will occupy less than 0.01%
of the albumin molecules [22]. Therefore, the pharmacokinetic
properties of IDeg would not be affected in vivo by other
albumin-bound drugs or by even very large changes in albumin
concentration. The mode of protraction of IDeg contrasts with
other basal insulin preparations, which achieve their prolonged
action through different mechanisms, such as pH-dependent
crystallisation (IGlar) [23] and local albumin binding (IDet) [20].
2.1. Pharmacokinetic and pharmacodynamic properties of
insulin degludec
At steady state, IDeg has a half-life after SC administration
of approximately 25 h [24,25]. As a result, the duration of
action of IDeg at steady state exceeds 42 h [22,24,26] compared
with the mean duration of action of IGlar of 20.5 h [27].
Pharmacodynamic analyses have further shown that the
glucose-lowering effect of IDeg is evenly distributed across the
entire 24-h dosing interval [24,28]. With IDeg, steady state is
reached within three days of once-daily administration [24],Fig. 1 – Schematic representation of the hypothesis for the mod
injected subcutaneously as a zinc phenol formulation containin
of phenol changes the IDeg hexamers to a T6 configuration and
these chains break down into dimers, which quickly dissociatetherefore dose titrations can be safely carried out once-weekly
to avoid overshooting the glycaemic target.
Due to the prolonged pharmacodynamics of IDeg, under
steady-state conditions the overlapping effect of daily injec-
tions results in less variability in glucose-lowering effect [29].
In patients with T1DM, it has been shown that the day-to-day
within-subject variability in glucose lowering effect is four-
times less with IDeg compared with IGlar, theoretically
translating into more predictable glycaemic control [26]. A
flat and stable glucose-lowering effect with IDeg that is evenly
distributed across the 24-h dosing interval has also been
shown in patients with T2DM [24].
Importantly, the ultra-long pharmacokinetic and pharma-
codynamic properties of IDeg observed in patients with T1DM
and T2DM are maintained in various subpopulations, such as
the elderly and those with hepatic or renal impairment
(including those with end-stage renal disease) [30–32]. The
pharmacokinetic and pharmacodynamic properties of IDeg
are maintained in both of its formulations, U100 and U200 [33].
As of January 2015, IDeg has regulatory approval in
Argentina, Aruba, Azerbaijan, Bangladesh, Bosnia & Herzego-
vina, Brazil, Chile, Colombia, Costa Rica, El Salvador, the EU
[34], Honduras, Hong Kong, Iceland, India, Israel, Japan,
Kazakhstan, Lebanon, Lichtenstein, Macedonia, Mexico,
Nepal, Norway, Russia, South Korea, Switzerland and the
UAE. Approval in the USA is pending further cardiovascular
data in the form of a dedicated cardiovascular outcomes trial
(CVOT), which is currently ongoing (NCT01959529).
2.2. Co-formulation with insulin aspart
Another pharmacological property of IDeg is that it can be
combined with the rapid-acting insulin analogue IAsp withoute of retarded absorption of insulin degludec (IDeg). IDeg is
g the IDeg di-hexamer in the T3R3 conformation. Rapid loss
 multi-hexamer chains form. With slow diffusion of zinc,
 into readily absorbed monomers.
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degludec/insulin aspart (IDegAsp), comprised of 70% IDeg
and 30% IAsp, is the first soluble insulin combination product
that provides a pharmacodynamic profile that reflects the
prandial insulin profile of IAsp superimposed on the long
and stable profile of IDeg in a single injection [35]. IDegAsp
can be administered once- or twice-daily with the main
meal(s) [36]. Twice-daily IDegAsp is associated with reduced
risk of hypoglycaemia compared to premixed insulins and
reduced treatment burden compared with basal-bolus
therapy when dosed once-daily, in subjects with T2DM
[37–39]. The administration of IDegAsp with a single meal,
with additional bolus rapid-acting analogue injections at the
remaining mealtimes, can further simplify the treatment
regimen in T1DM by reducing the number of daily injections
compared with standard basal-bolus therapy (IDet + IAsp)
[40].
2.3. Combination with liraglutide
IDeg can also be combined with liraglutide, a once-daily GLP-1
analogue, in IDegLira, a novel, once-daily, fixed-ratio combi-
nation therapy (one dose step of IDegLira comprises 1 U of
IDeg and 0.036 mg of liraglutide). IDegLira combines and
preserves two complementary modes of action addressing the
multiple underlying pathophysiological defects in T2DM
[41,42]. In patients with T2DM, IDegLira leads to effective
glycaemic control via reductions in FPG and postprandial
glucose throughout the day and after all meals [43,44]. It is
also associated with a significant reduction in body weight vs
IDeg, comparable or lower risk of confirmed hypoglycaemia
vs IDeg and an improved gastrointestinal side effect profile,
particularly nausea, compared with liraglutide [43,44]. There-
fore, IDegLira in a single pen and for once-daily injection
offers patients a simple therapy intensification option.
IDegLira was recently approved by the European Medicines
Agency (EMA) for the treatment of patients with T2DM
[45].
3. Clinical evidence
The implications of the promising pharmacokinetic and
pharmacodynamic characteristics of IDeg have been inves-
tigated in a large clinical trial programme (BEGIN1) involving
more than 11,000 patients with T1DM and T2DM (Table 1).
IGlar was generally used as the comparator basal insulin,
in the phase 3 studies, and overall, the randomisation
of patients treated with IDeg vs IGlar was between 2:1 and
3:1. Nine phase 3a randomised, controlled, open-label,
multicentre trials with a ‘treat-to-target’ design (in order
to meet FDA recommendations for non-inferiority of new
insulins) have been carried out. In all of the studies, insulin
dose titration included adjustment of insulin doses to
achieve pre-breakfast self-measured blood glucose (SMBG)
values of 4–5 mmol/L (70–90 mg/dL). In addition, the same
definition of confirmed hypoglycaemia (plasma glucose
<3.1 mmol/L [<56 mg/dL] or severe hypoglycaemia) was
used throughout the programme (see Appendix A). This
definition of hypoglycaemia (that is, a low hypoglycaemiacut-off level due to the low target plasma glucose level)
was chosen to avoid false positives and to discriminate
hypoglycaemia with neuroglycopenic symptoms. Similarly,
nocturnal hypoglycaemia was defined as confirmed episodes
of hypoglycaemia occurring between 00.01 h and 05.59 h, in
order to minimise confounding by any hypoglycaemia related
to the prandial insulin component in the basal-bolus studies.
3.1. Efficacy of insulin degludec in subjects with type 1
diabetes
Data from the studies in subjects with T1DM have shown that
when titrated to the same glycaemic targets, IDeg is non-
inferior to IGlar in terms of the mean reduction in HbA1c
concentrations [46,47]. Subjects on a twice-daily regimen
converted their total daily insulin dose 1:1 with IDeg, but
reduced IGlar by 20%. The dose was converted on a 1:1 basis
in subjects switching from a once-daily schedule [46,47]. In the
basal-bolus trial in T1DM (IDeg vs IGlar), mean daily basal,
daily bolus and total daily doses of insulin were significantly
reduced by 14% ( p < 0.0001), 10% ( p = 0.016) and 11%
( p < 0.0001), respectively, in the IDeg group compared with
the IGlar group at end of trial [46]. These findings support the
recommendation for reducing the dose of IDeg when switch-
ing patients from IGlar and are further reflected in a slightly
higher rate of daytime hypoglycaemia being observed with
IDeg [46] upon initiation compared to IGlar, as discussed below
(Sections 3.3.1 and 4.1). Mean reductions in FPG levels were
similar in subjects receiving IDeg and IGlar, with no statisti-
cally significant between-treatment differences reported in
subjects with T1DM [46,47].
3.2. Efficacy of insulin degludec in subjects with type 2
diabetes
Studies in subjects with T2DM confirmed that IDeg is non-
inferior to IGlar in terms of reducing HbA1c concentrations in
both insulin-naive [48,49] and previously insulin-exposed
patients [50]. Clinical data from insulin-naive patients with
T2DM [48,51] also indicate that, as seen in T1DM studies, the
total daily insulin dose at the end of the trial was lower in
subjects who received IDeg compared with those who received
IGlar. There was also a trend towards lower FPG levels with
IDeg compared with IGlar in five trials with T2DM [39,49–52],
which reached statistical significance in three of them
[49,51,52].
3.3. Effects of insulin degludec on hypoglycaemia
Based on prior discussions with, and subsequent review by the
regulatory authorities, a pre-planned meta-analysis was
conducted of pooled and analysed subject-level data from
seven phase 3a trials (see Table 1) [53].
The primary endpoint in the meta-analysis was overall
confirmed hypoglycaemia; although, episodes of nocturnal
confirmed hypoglycaemia and severe hypoglycaemia were
also evaluated (see Appendix A). In all of the analysed trials,
‘confirmed hypoglycaemia’ was defined as either a plasma
glucose concentration of <3.1 mmol/L (56 mg/dL) or an
episode of severe hypoglycaemia (requiring assistance).
Table 1 – Summary of the phase 3a clinical trials in the BEGINW clinical programme with insulin degludec (IDeg).
Gough et al. 
(BEGINTM: LOW 
VOLUME) [51] 
T2DM insulin-
naive 
 IDeg 200 U/mL OD vs IGlar 
OD (+ metformi n ± dipetidyl 
peptidase) 
26 w IDeg 1.3%; IGlar 
1.3% 
(ETD IDeg vs IGlar 
0.04%; non-
inferior) 
IDeg 3.7 mmol/L; IGlar 
3.4 mmol/L (ETD IDeg vs  
IGlar -0.42 mmol/L; p < 
0.05) 
IDeg 1.22 vs IGlar 1.42 
episodes per PYE; ERR 
0.86, p = 0.46  
Onishi et al. 
(BEGINTM: 
ONCE ASIA) 
[48] 
T2DM insulin-
naive 
IDeg OD vs Glar OD (+ oral  
antidiabetic drugs)  
26 w IDeg 1.24%; IGlar  
1.35% (ETD IDeg  
vs IGlar 0.11%; 
non-inferior) 
IDeg 2.88 mmol/L; IGlar 
2.97 mmol/L (ETD IDeg  
vs IGlar -0.09 mmol/L; p = 
0.59) 
IDeg 3.0 vs IGlar 3.7 
episodes per PYE; ERR 
0.82,  p = 0.20  
Philis-Tsimikas 
et al. (BEGINTM: 
EARLY) [73] 
T2DM IDeg OD vs sitagliptin (+  
oral antidiabetic drugs) 
26 w IDeg 1.52%; 
sitagliptin 1.09% 
(ETD IDeg vs 
sitagliptin 0.43%; 
superior)   
IDeg 3.41 mmol/L; 
sitagliptin 1.24 mmol/L 
(ETD IDeg vs sitagliptin -
2.17 mmol/L; superior) 
IDeg 3.1 vs sitagliptin 1.3 
episodes per PYE; ERR 
3.81, p = nr  
Author (study 
name) Population Tr ial treatments (n) Duration
Reduction in 
HbA1c
Reduction in FPG Confirmed hypoglycaemic episodes
Heller et al. 
(BEGINTM: T1) 
[46]
T1DM insulin-
treated
IDeg OD (472) vs IGlar OD 
(157) plus IAsp TI D
52 w IDeg 0.40%;  IGlar  
0.39% (ETD IDeg  
vs IGlar -0.01%;  
non-inferior)
IDeg 1.3 mmol/L; IGlar 
1.4 mmol/L (ETD IDeg vs 
IGlar -0.33 mmol/L; p = 
0.35)
IDeg 43 vs IGlar 40 
episodes per PYE; ERR 
1.07, p = 0.48
Mathieu et al. 
(BEGINTM: Flex 
T1) [47]
T1DM insulin-
treated
IDeg Forced-Flex OD (164) 
vs IDeg OD (165) and IGlar 
OD, (164) Extension: IDeg 
Free-Flex OD vs IGlar OD. 
All arms + IAsp TID
26 w (+  26-
w 
extension)
IDeg Forced-Flex 
0.40%, IDeg 
0.41%, IGlar 
0.58%
(ETD IDeg Forced-
Flex vs IGlar 
0.17%; non-
inferior)
IDeg Forced-Flex 1.28 
mmol/L; IDeg 2.54 
mmol/L; IGlar 1.33 
mmol/L (ETD IDeg  
Forced-Flex vs IGlar -
0.05 mmol/L; p = ns )
IDeg (including both 
Forced-Flex and Free-Flex) 
68.1 vs IGlar 63.4 episodes 
per PYE; ERR 1.09, p = ns
Garber et al. 
(BEGINTM: BB) 
[50]
T2DM insulin-
treated
IDeg OD (744) vs IGlar OD 
(248)
52 w IDeg 1.1%; IGlar: 
1.2%
(ETD IDeg vs IGlar 
0.08%; non-
inferior)
IDeg 2.3 mmol/L; IGlar 
2.0 mmol/L (ETD IDeg vs 
IGlar -0.29 mmol/L; p = 
0.1075)
IDeg 11.1 vs IGlar: 13.6 
episodes per PYE; ERR 
0.82, p = 0.035 9
Meneghini et al. 
(BEGINTM: 
FLEX) [52]
 T2DM (insulin  
naive or 
insulin-treated)
IDeg Flex OD (229), IDeg  
OD (228), IGlar OD (230)
26 w IDeg Flex 1.28%;  
IDeg 1.07%; IGlar  
1.26%
(ETD IDeg Flex vs 
IGlar 0.04%; non-
inferior)
IDeg Flex 3.2 mmol/L; 
IDeg 3.0 mmol/L; IGlar 
2.8 mmol/L (ETD IDeg  
Flex vs IGlar -0.42 
mmol/L; p = 0.04)   
IDeg Flex 3.6 vs IDeg 3.6 
vs IGlar 3.5 episodes per 
PYE; ERR 1.03, p = ns
Zinman et al. 
(BEGINTM: Once 
Long) [49]
T2DM insulin-
naive
IDeg OD vs IGlar OD (+ 
metformin)
 52 w IDeg 1.06%;  IGlar  
1.19%
(ETD IDeg vs IGlar 
0.09%; non-
inferior)
IDeg 3.8 mmol/L; IGlar 
3.3 mmol/L (ETD IDeg vs 
IGlar -0.43 mmol/L; p = 
0.005)
IDeg 1.52 vs IGlar 1.85 
episodes per PYE; ERR 
0.82, p = 0.10 3
ERR, estimated rate ratio; ETD, estimated treatment difference; FPG, fasting plasma glucose; IAsp, insulin aspart; IDeg, insulin degludec; IGlar,
insulin glargine; nr, not reported; ns, not significant; PYE, patient-year of exposure; OD, once daily; TID, three times daily; T1DM, type 1
diabetes mellitus; T2DM, type 2 diabetes mellitus; w, weeks. Trials shaded in blue were included in the meta-analysis of hypoglycaemia rates,
published by Ratner et al. [53], except the extension of the BEGIN Flex T1 trial, which was not included in the meta-analysis.
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In the T1DM trials included in the meta-analysis [46,47] there
was no significant difference between IDeg and IGlar in the
rate of overall confirmed hypoglycaemic episodes across the
overall treatment period, although it was slightly higher with
IDeg compared to IGlar (Fig. 2a) [53]. Absolute rates of
confirmed hypoglycaemic episodes ranged from 53 to 93 per
patient-year of exposure (PYE) with IDeg and from 49 to 83 per
PYE with IGlar [53]. The higher rate of hypoglycaemic episodes
seen with IDeg compared to IGlar appears to be mostly
concentrated in the first four weeks of the trials, and during
daytime, when the dose of IGlar was reduced initially while
that of IDeg was not (as discussed in Section 4.1). In the
maintenance period (defined as the period following active
dose titration from 16 weeks to the end of treatment when
typically only minor adjustments to insulin dose are required)there was no increase in hypoglycaemia with IDeg compared
to IGlar. Overall, a lower rate of nocturnal hypoglycaemia with
IDeg compared with IGlar was observed in subjects with T1DM
(Fig. 2b). The reduction in estimated rate ratio (ERR) in
nocturnal hypoglycaemic episodes reached statistical signifi-
cance in the maintenance period (ERR 0.75; 95% CI 0.60, 0.94)
(Fig. 2b) [53].
In a recent randomised, two-period, crossover study in 28
subjects with T1DM and normal hypoglycaemia awareness,
hypoglycaemia was induced by administering three-times the
usual daily insulin dose (IDeg or IGlar). The study showed that,
despite moderate increases in counter-regulatory hormone
responses with IDeg compared with IGlar, the rates of recovery
from hypoglycaemia were similar with IDeg and IGlar, and the
two basal insulins elicited comparable symptomatic and
cognitive responses to induced hypoglycaemia [54].
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Fig. 2 – Hypoglycaemia rate ratio in subjects with type 1 (T1DM) and type 2 (T2DM) diabetes receiving insulin degludec (IDeg)
or insulin glargine (IGlar). Data presented are estimated rate ratios (IDeg/IGlar) with 95% confidence intervals of (a) overall
confirmed hypoglycaemic episodes, (b) nocturnal confirmed hypoglycaemic episodes and (c) severe hypoglycaemic
episodes. Asterisks indicate significantly lower estimated rate ratio with IDeg compared with IGlar based on 95%
confidence intervals (figures based on data from Ratner et al. [53]).
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In subjects with T2DM, the episodes of hypoglycaemia ranged
from 1 (basal only) to 13 (basal-bolus) per PYE with IDeg, and
from 1 (basal only) to 15 (basal-bolus) per PYE with IGlar [53].
The meta-analysis found that the rates of overall andnocturnal confirmed hypoglycaemia were significantly re-
duced with IDeg in insulin-naive subjects with T2DM
compared with IGlar (ERR 0.83; 95% CI 0.70, 0.98 and ERR
0.64; 95% CI 0.48, 0.86, respectively) (Fig. 2). In the overall
population of insulin-naive and insulin-experienced subjects
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hypoglycaemia were 17% and 32% lower, respectively (Fig. 2b).
The reduction in the ERR of overall (Fig. 2a) and nocturnal
hypoglycaemia (IDeg/IGlar) (Fig. 2b) was even more pro-
nounced in the maintenance period. A reduction in the
relative risk of severe hypoglycaemia rates in favour of IDeg
was observed in insulin-naive subjects with T2DM (ERR 0.14;
95% CI 0.03, 0.70) (Fig. 2c) [53]. However, the incidence of such
severe episodes remains very low in both groups as would be
expected due to the exclusion of patients with a history
of severe hypoglycaemia in clinical trials. In addition, no
statistically significant differences in hypoglycaemia were
observed in subjects receiving U200 IDeg compared with IGlar
(1.22 per PYE versus 1.42 per PYE; ERR 0.86; 95% CI 0.58, 1.28;
p = 0.46) [51].
The meta-analysis therefore confirmed that there is a
statistically significant 9% reduction in risk of overall
hypoglycaemia and a 26% reduction in the risk of nocturnal
hypoglycaemia with IDeg compared to IGlar at equivalent
HbA1c levels in the pooled population of patients with T2DM
and T1DM [53]. It has been reported that higher rates of
confirmed hypoglycaemia are associated with greater within-
subject variability in FPG levels in subjects with T1DM and
T2DM [55]. The reduction in hypoglycaemia associated with
IDeg use might be partly attributed to the reduced pharmaco-
dynamic variability in glucose-lowering effect compared to
IGlar [53] that has been reported in subjects with T1DM [26]
and in those with T2DM [56]. Further studies are required to
confirm this hypothesis and to validate the benefit of IDeg in
real-life studies.
3.3.3. Treatment satisfaction with insulin degludec in patients
with type 1 or 2 diabetes and recurrent hypoglycaemia
The clinical trials discussed above, comparing IDeg and IGlar,
excluded patients with severe recurrent hypoglycaemia [53], a
population who might benefit most from a basal insulin with
more stable glucose-lowering effects and a reduced risk of
hypoglycaemia. However, this aspect has been addressed in
early, real-world observational studies in patients with T1DM
or T2DM and recurrent hypoglycaemia. Switching patients
with frequent hypoglycaemia to IDeg has been shown to be
associated with a reduction in the frequency of hypoglycaemic
events and improved glycaemic control [57,58]. In these
patients, switching to IDeg improved patients’ treatment
satisfaction [57].
3.3.4. Exercise-related hypoglycaemia
Exercise-related hypoglycaemia is a concern for patients with
diabetes since the higher glucose requirement and insulin
sensitivity during exercise can increase the risk of hypogly-
caemia [59]. To investigate this further, a randomised, single-
centre, open-label, two-period, multiple-dose, crossover trial
was conducted to compare the effect of exercise (30 min
bicycle exercise at 65% VO2peak) on blood glucose between IDeg
and IGlar, both in combination with mealtime IAsp, in 40
subjects with T1DM [60]. The study found that the risk of
exercise-related hypoglycaemia was low and similar with IDeg
compared to IGlar. Moreover, no episodes of hypoglycaemia
were reported during the exercise phase with either IDeg or
IGlar and the incidence of hypoglycaemia in the 24 h afterexercising was also similar with both basal insulins [60].
Furthermore, a recent analysis of exercise-related hypogly-
caemia events from seven randomised, open-label, treat-to-
target, clinical trials in subjects with T1DM and T2DM
comparing IDeg with IGlar (both given once-daily) reported
that IDeg did not lead to an increased risk of self-reported
exercise-related hypoglycaemia compared with IGlar [61].
3.4. Cardiovascular safety
In accordance with the FDA 2008 CV Risk Guidance recom-
mendations, a pre-specified meta-analysis of major adverse
cardiovascular events (MACE) in the IDeg phase 3 trials was
carried out. In total, 80 patients in 16 clinical trials involving
8918 patients [34] experienced treatment-emergent MACE (53
in patients receiving IDeg or IDegAsp and 27 on comparator
insulins). The incidence rates were 1.48 events per 100 PYE in
patients treated with IDeg or IDegAsp and 1.44 events per 100
PYE in patients treated with comparator basal insulins.
Subsequent post-hoc analyses of MACE data in clinical trials
up to May 2012 were conducted. As these data neither
confirmed nor excluded the possibility for an increased
cardiovascular risk with IDeg in comparison with IGlar, the
DEVOTE clinical trial was subsequently initiated to define
better the cardiovascular profile of IDeg (and IDegAsp) in
patients at high risk of cardiovascular events (NCT01959529).
In addition, IDeg has been shown not to alter classical
cardiovascular risk factors such as low density lipoprotein,
high density lipoprotein and blood pressure compared with
the comparator [62].
3.5. Quality of life
QoL assessment using the Short-Form 36 (SF-36) Health Survey
version 2 questionnaire demonstrated significant improve-
ments in both the physical (specifically bodily pain domain
score) and mental (specifically vitality) components of the
SF-36 with IDeg compared with IGlar ( p < 0.05 or Cohen’s
effect size 0.4–0.5) [50,63–65]. Similar findings in QoL have
been reported with the U200 formulation of IDeg [51].
3.6. Cost-effectiveness of degludec
Several recent papers have demonstrated the cost–effective-
ness of IDeg compared to IGlar [66–68]. A cost–utility model
based on both data from a meta-analysis of phase 3 trials [53]
and a questionnaire-based study conducted in Sweden,
reported that IDeg was associated with greater quality-
adjusted life year (QALY) gains in patients with T1DM (0.31
vs 0.26 QALYs gained for IGlar), patients with T2DM requiring
basal insulin (0.76 vs 0.69 QALYs gained) and patients with
T2DM requiring basal-bolus treatment (0.56 vs 0.47 QALYs
gained) after one year of treatment [66]. While pharmacy costs
for IDeg were higher, these were partially offset by cost savings
due to reduced insulin doses, reduced direct costs of
hypoglycaemia, reduced productivity losses and reduced
costs of blood glucose monitoring [66]. Depending on the
diabetic population (T1DM, T2DM basal-only insulin or T2DM
basal-bolus insulin), IDeg was associated with incremental
cost–effectiveness ratios of SEK 19,766, SEK 10, 082 and SEK 36,
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within the previously reported willingness-to-pay threshold of
SEK 500,000 per QALY gained.
Similarly, two UK-based studies examined cost–utility of
IDeg compared to IGlar in the context of the UK national
health service, in patients with T1DM [68] and T2DM [67],
using hypoglycaemia rates for IDeg and IGlar from a pre-
planned meta-analysis of phase III clinical trials [53]. In both
studies, IDeg was within the previously reported willing-
ness-to-pay threshold of £20,000 to £30,000 per QALY. Of
note, sensitivity analyses demonstrated that using higher
baseline non-severe hypoglycaemic events resulted in
greater cost–effectiveness for IDeg compared to IGlar
[67,68]. This is of particular importance as clinical trials,
due to their controlled nature and exclusion criteria, are
likely to report lower hypoglycaemia rates than those found
in clinical practice.
In the developing world there is limited available evidence
concerning cost–effectiveness. Hypoglycaemia and blood
glucose monitoring contribute to the cost burden of diabetes,
both for healthcare systems and for the individual patient.
Results from the multinational, non-Western A1chieve study
previously showed that, for insulin-experienced patients,
switching to modern insulin analogues was associated with
a reduction in hypoglycaemia rates [69]. More recently, the
large-scale, observational Hypoglycaemia Assessment Tool
(HAT) study, conducted across North America, Latin America,
Europe and South East Asia and involving over 27000 patients,
has reported higher hypoglycaemia rates than in previous
studies limited to Europe and North America [70], highlighting
the global burden of hypoglycaemia, particularly for countries
with limited healthcare resources. Since lower rates of
hypoglycaemia have been demonstrated for IDeg and less
frequent blood glucose monitoring is needed compared to
IGlar, use of IDeg could potentially reduce these costs.
However, no cost–utility analysis for IDeg has yet been
published for countries outside of Europe, and hence the
cost–effectiveness of IDeg in developing countries has yet to be
demonstrated.
4. Use of insulin degludec in clinical practice
IDeg is licensed for the treatment of adult patients (18 years)
with T1DM and T2DM [34]. Simulated pharmacokinetic and
pharmacodynamic profiles at steady state indicate a similar
exposure and glucose-lowering effect of IDeg over a 24-h
period regardless of the site of injection [25].
In patients with T1DM, IDeg should be administered once-
daily in combination with a prandial fast-acting insulin to
provide insulin coverage during mealtimes [34]. In patients
with T2DM, IDeg can be administered alone, in combination
with oral hypoglycaemic agents, GLP-1 analogues or with
bolus insulin, as supported by clinical evidence [47–50]. Based
on the phase 3 trials, the recommended starting dose of IDeg in
insulin-naive patients with T2DM is 10 unit once-daily with
subsequent adjustments and individualisation [34], although
it is important to apply clinical judgement (considering the
body mass index and the levels of insulin resistance of each
subject) when determining the starting dose.4.1. Switching to insulin degludec
Patients with either T1DM or T2DM can switch from other
insulin-based regimens to IDeg, as supported by evidence
from clinical trials [46,50]. However, switching between
insulin products should be done under medical supervision
and patients should be aware that dose adjustment may be
required [34]. Before, during and in the weeks following a
switch to IDeg, FBG levels should be monitored closely [34].
When switching patients from other basal insulins to IDeg,
providers will need to manage the brief period between the
loss of the previous basal insulin’s effect and attainment of
steady state with IDeg. During this period, patients may
observe higher blood glucose values for 3–5 days following the
switch to IDeg, and this possibility should be discussed with
the patient prior to the switch. In addition, adjustments to
dose and timing of concurrent short- or rapid-acting insulin
analogues or other glucose-lowering treatment may also be
required [34]. The authors have also noticed that as the effect
of IDeg stabilises, some patients may experience a progressive
(and in some cases marked) reduction in prandial insulin
doses.
Switching to IDeg from other once-daily basal insulins, doses
can usually be done on a 1:1 basis [34]. Based on their clinical
experience, the authors suggest that the dose be reduced by
20% if transitioning from a twice-daily basal schedule (and
depending upon individual glycaemic response), as recom-
mended for IGlar [17]; if switching from a once-daily basal
insulin schedule, a dose reduction can be considered also, if the
patient has a low HbA1c value. In addition, prandial insulin
doses might also need to be adjusted to reduce the risk of
hypoglycaemia during the day when switching to IDeg–
specifically, the pre-breakfast prandial dose, especially when
aiming for a strict FPG target as defined in the phase 3 trials
(4.0–5.0 mmol/L). Further dose adjustment guidance when
switching from other insulin products is provided in Fig. 3.
4.2. Titration of insulin degludec in patients with type 1 or
type 2 diabetes
Dose adjustment with IDeg can be carried out once-weekly to
achieve individual patient targets (Fig. 4). The treat-to-target
goal and insulin dose adjustment are based around an
individual’s pre-breakfast FPG (or SMBG) level. A calculated
mean FPG from the preceding 2 days can be compared to
desired glycaemic goals and basal insulin doses can be adjusted
up or down by 2 units, as shown in Fig. 4, to achieve target.
4.3. Flexibility in dosing of insulin degludec in patients
with type 1 or type 2 diabetes
Anticipating or delaying a scheduled daily dose of basal insulin
will affect its concentration in the circulation; however, this
effect will be less for insulin preparations, such as IDeg, with a
longer half-life and duration of action.
Similar to IGlar, IDeg should be administered once-daily,
preferably at the same time every day; however, on occasions
when administration at the same time of the day is not
possible, IDeg allows for flexibility in the timing of dose
administration provided a minimum of 8 h between injections
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Is the patient receiving once-daily
or twice-daily basal insulin?
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Is the patient’s
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Unit-to-unit
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Twice-daily Basalinsulin Basal–bolus Premix Self-mix
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when switching from a twice-daily basal insulin 
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schedule, if the patient has a low HbA1c value
‡
Unit-to-unit adjustments can be made 
followed by individual dose adjustments.†
A 20% dose reduction may be considered 
when switching from a twice-daily 
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Fig. 3 – Dose adjustment algorithm providing guidance when switching to insulin degludec (IDeg) from other insulin-based
products. * With further guidance from the patient’s physician. y Close glucose monitoring is recommended during the
transfer and in the following weeks. Doses and timing of concurrent rapid- or short-acting insulin products or other
concomitant antidiabetic treatment may need to be adjusted. z Based on individual glycaemic response and guidance from
the patient’s physician.
Fig. 4 – Dose titration recommendations for insulin degludec (IDeg). * FPG measurements must be from the preceding 2 days.
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and T2DM, who were instructed to inject IDeg at forced
intervals varying between 8 and 40 h, compared to IGlar,
which was consistently injected at the same time every day
[47,52]. The large variation in the injection time of IDeg did not
compromise its efficacy or safety when compared to IGlar
taken at the same time each day. The broader dosing window
for IDeg can allow more flexibility in the timing of insulin
administration. The daily IDeg dose can be either advanced or
postponed in order to accommodate different patient life-
styles, with no negative impact on glycaemic control, provided
a minimum interval of 8 h is maintained between IDeg
injections [34]. It needs to be noted that back-to-back
administrations of IDeg every 8 h will increase the risk of
excess insulin and subsequent hypoglycaemia. A broader
dosing window for insulin administration may allow patients
to use a more convenient injection schedule without
compromising either control of blood glucose levels or safety
[52]. In the event of a missed dose, patients are advised to
administer IDeg as soon as this is realised (unless this would
result in a difference of less than 8 h between injections) and
resume their usual once-daily dosing schedule [34].
4.4. Administration of high insulin doses at lower
volumes
Many patients with T2DM may require larger insulin doses to
overcome insulin resistance. The delivery of large insulin
doses often requires the administration of an increased
number of injections or high injection volumes which can
cause substantial pain at the injection site [71]. As discussed,
there are two different formulations of IDeg: 100 units/mL
(U100) and 200 units/mL (U200), which have been shown to be
bioequivalent [33]. The latter (IDeg U200) delivers half the
volume of the U100 formulation and allows for administration
of up to 160 units in one dose.
4.5. Administration of insulin degludec in special
populations
IDeg is licensed for use in elderly patients (65 years of age)
and is also suitable for use in patients with renal or hepatic
impairment [34] as supported by clinical evidence, indicating
that the pharmacokinetic characteristics of IDeg are preserved
in these patient populations [30–32]. However, as recom-
mended for other basal insulins [16,17], glucose-monitoring
should be performed more frequently in these specific patient
populations [34]. The safety and efficacy of IDeg in children
and adolescents <18 years of age are currently being
established [72]; in addition, there is currently no clinical
experience with the use of IDeg in pregnant women [34].
5. Conclusions
IDeg is a new basal insulin with an ultra-long duration of
action that exceeds 42 h, with a flat and stable glucose-
lowering effect and reduced within-subject variability, result-
ing in consistent 24-h basal insulin coverage from a once-daily
injection. Clinical evidence from a large phase 3a clinical trialprogramme in patients with T1DM and T2DM with a treat-to-
target design have demonstrated that IDeg provides effective
glycaemic control, similar to that observed with IGlar, but with
lower rates of hypoglycaemia, in particular nocturnal hypo-
glycaemia, although the rates of symptomatic hypoglycaemia
were low with both basal insulins due to the exclusion of
subjects with recurrent hypoglycaemia. The consistent 24-h
glucose-lowering effect and the reduction in hypoglycaemia
that may be a result of low within-subject variability in FPG
levels with IDeg, allow a broader, more flexible dosing window
compared to other basal insulins, without compromising
glycaemic control or safety. This flexibility in dose timing
combined with an effective once-daily administration makes
IDeg a less restrictive and more convenient basal insulin
treatment option for both patients with T1DM and T2DM. IDeg
is available in a U200 formulation (in addition to U100), which
provides an option for large insulin doses to be administered
at lower volumes. In addition, the availability of IDeg in
combination with IAsp or liraglutide offer further potential for
improved glycaemic control and a reduced number of daily
injections for patients.
Overall, the clinical benefits of tight glycaemic control,
reduced nocturnal hypoglycaemia and a more flexible
treatment regimen associated with IDeg may help to over-
come the barriers associated with initiation of basal insulin
therapy and address the current unmet needs. By offering a
basal insulin with a more flexible treatment schedule,
as desired by the patient, IDeg may improve treatment
adherence leading to better long-term clinical outcomes in
patients with T1DM and T2DM.
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